Medicaid and CHIP Will No Longer Cover Gender‑Affirming Care — Mehmet Oz and RFK Jr. Back the Rule

The administration announced that Medicaid and the Children’s Health Insurance Program (CHIP) will no longer fund gender-affirming care for transgender youth. The rule ends federal coverage for puberty blockers, cross-sex hormones and transition-related surgeries, cutting off access for thousands of adolescents who rely on public insurance for medically necessary care.

Centers for Medicare & Medicaid Services Administrator Mehmet Oz framed the change as a protection of children. In a statement he said:

"Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits. By cutting off federal funds for these sex-rejecting procedures, we're following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish."

The administration’s position conflicts with the international standards of care that have guided treatment for youth with gender dysphoria for roughly two decades. Major medical organizations — including pediatric and mental health associations in multiple countries — generally support carefully supervised, evidence-based approaches to gender-affirming care for young people when clinically indicated.

Evidence, Controversy and Policy

Critics say the rule reflects a political agenda to restrict access to transition-related care. Research indicates that denial of medically advised gender-affirming care is associated with worse mental-health outcomes and a higher risk of suicide among transgender youth. Advocates argue that removing coverage will exacerbate those risks, particularly for low-income families who cannot afford private treatment.

The Department of Health and Human Services cited the so-called Cass Review — a British analysis produced by an official with no clinical experience in transgender healthcare — as part of its rationale. That review has been widely disputed and critiqued by clinicians and researchers for methodological flaws and limited applicability.

HHS Secretary Robert F. Kennedy Jr. echoed CMS’s language in his own statement:

"Today, we are ending federal taxpayer funding for sex-rejecting procedures on children."

The use of the term "sex-rejecting" is a deliberate counter to the established term "gender-affirming," and many advocates say it signals a refusal to recognize transgender youths’ identities. Opponents of the rule warn it effectively endorses conversion-style approaches by restricting access to medical and social supports that clinicians deem appropriate.

Human Cost: Cases That Resonated

The policy shift revived painful reminders of young people lost to suicide. The death of May Pollard, an Idaho teenager, came amid intense state-level efforts to restrict transgender minors’ access to care. NBC News reported that Idaho lawmakers proposed more than four dozen bills related to LGBTQ rights in the years before Pollard’s death, and 15 measures were signed into law — many limiting access to puberty blockers, hormone therapy and classroom instruction about sexual orientation and gender identity.

Similarly, the 2014 death of Leelah Alcorn — and the viral suicide note she left behind — helped catalyze broader public attention to the struggles of transgender youth. Alcorn’s plea, "My death needs to mean something. Fix society. Please," continues to be cited by advocates calling for policies that protect, rather than punish, transgender young people.

What This Means

Supporters of the rule say it protects children from unproven and risky interventions. Opponents, including many clinicians and medical organizations, contend the change is politically motivated and ignores decades of clinical practice and research. Either way, the rule will directly affect teenagers dependent on public insurance — a group that includes many low-income and otherwise vulnerable families.

As this policy takes effect, advocates, clinicians and families are likely to continue challenging the decision in courts and public forums. For transgender youth and their loved ones, the immediate concern is access to timely, evidence-based medical and mental-health care.

Sources: Official statements from CMS and HHS; reporting on May Pollard and Leelah Alcorn; critiques of the Cass Review and summaries of clinical guidance from pediatric and mental-health organizations.